Suggested remit: To appraise the clinical and cost effectiveness of aducanumab within its marketing authorisation for treating mild cognitive impairment (MCI) in early Alzheimer’s disease.
Status Proposed
Process STA 2018
ID number 75

Provisional Schedule

Scoping workshop 16 November 2020 (14:00)

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
22 September 2020 - 20 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance